Pakistan Randomized and Observational Trial to Evaluate Coronavirus Treatment (PROTECT) of Hydroxychloroquine, Oseltamivir and Azithromycin to treat newly diagnosed patients with COVID-19 infection who have no comorbidities like diabetes mellitus: A structured summary of a study protocol for a randomized controlled trial
AbstractObjectivesTo evaluate the effectiveness of Hydroxychloroquine Phosphate/Sulfate (200 mg orally 8 hourly thrice a day for 5 days),versus oseltamivir (75 mg orally twice a day for 5 days), andversus Azithromycin (500 mg orally daily on day 1, followed by 250 mg orally twice a day on days 2-5) alone and in combination (in all seven groups), in clearing the coronavirus (COVID-19) nucleic acid from throat and nasal swab and in bringing about clinical improvement on day 7 of follow-up (primary outcomes).Trial DesignAn adaptive design, set within a comprehensive cohort study, to permit flexibility in this fast-changing cl...
Source: Trials - August 7, 2020 Category: Research Source Type: clinical trials
Administration of Allogenic UC-MSCs as Adjuvant Therapy for Critically-Ill COVID-19 Patients
Conditions: COVID; Pulmonary Infection; Sars-CoV2 Interventions: Drug: Oseltamivir; Drug: Azithromycin; Biological: Umbilical Cord Mesenchymal Stem Cells Sponsor: Indonesia University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 7, 2020 Category: Research Source Type: clinical trials
Safety and Effectiveness of Mesenchymal Stem Cells in the Treatment of Pneumonia of Coronavirus Disease 2019
Condition: COVID-19 Pneumonia Interventions: Drug: Oseltamivir; Drug: hormones; Device: oxygen therapy; Procedure: mesenchymal stem cells Sponsor: Fuzhou General Hospital Active, not recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 1, 2020 Category: Research Source Type: clinical trials
